CompletedPhase 1NCT06307301

Study in ALS With Abatacept & IL-2

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The Methodist Hospital Research Institute
Principal Investigator
Jason Thonhoff, MD, PhD
The Methodist Hospital Research Institute
Intervention
Abatacept Injection [Orencia] and Proleukin (aldesleukin)(drug)
Enrollment
5 enrolled
Eligibility
18 years · All sexes
Timeline
2021 – 2024

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06307301 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis →

← Back to all trials